CA
ALNY icon

Calton & Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History

Calton & Associates’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-236
Closed -$32K – 372
2017
Q4 		$32K Buy
+236
New +$29.7K 0.01% 788

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Calton & Associates's ALNY Position: Q1 2018 in Review

Calton & Associates sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2018, closing a stake of 236 shares — an estimated $32K sold.

Calton & Associates first reported a position in ALNY in Q4 2017 and held it in 1 quarter. The position peaked at $32K in Q4 2017. 292 funds tracked by Wall St. Rank hold ALNY as of Q1 2018.

  • Calton & Associates reported no remaining Alnylam Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Calton & Associates sold 236 Alnylam Pharmaceuticals shares in Q1 2018, an estimated $32K.
  • Calton & Associates first reported a position in Alnylam Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Calton & Associates's Alnylam Pharmaceuticals position peaked at $32K in Q4 2017.
  • 292 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.